[go: up one dir, main page]

BRPI0409663A - método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento - Google Patents

método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento

Info

Publication number
BRPI0409663A
BRPI0409663A BRPI0409663A BRPI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A BR PI0409663 A BRPI0409663 A BR PI0409663A
Authority
BR
Brazil
Prior art keywords
systemic delivery
growth
bioactive compounds
lipid
derived bioactive
Prior art date
Application number
Other languages
English (en)
Inventor
Mark Kester
Thomas Stover
Tao Lowe
James Adair
Young Shin Kim
Original Assignee
Penn State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Penn State Res Found filed Critical Penn State Res Found
Publication of BRPI0409663A publication Critical patent/BRPI0409663A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/501—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/778—Nanostructure within specified host or matrix material, e.g. nanocomposite films
    • Y10S977/783—Organic host/matrix, e.g. lipid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"MéTODO E SISTEMA PARA O ENVIO SISTêMICO DE COMPOSTOS BIOATIVOS DERIVADOS DE LIPìDEO DE DETENçãO DE CRESCIMENTO". Sistema e método para a otimização do envio sistêmico de drogas bioativas derivadas de lipídeo de detenção de crescimento ou agentes de terapia de gene a um animal ou ser humano em necessidade dos referidos agentes, utilizando sistemas de montagem de nano escala, tais como lipossomas, dispersões de nano partículas re-absorvíveis e de não agregação, nano partículas de metal ou semicondutoras, ou materiais poliméricos tais como dendrímeros ou hidrogéis, cada um dos quais exibe aprimorada solubilidade de lipídeo, permeabilidade celular, e maior meia vida de circulação e perfil farmacocinético com alvo tumoral ou vascular.
BRPI0409663 2003-04-25 2004-04-26 método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento BRPI0409663A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46593803P 2003-04-25 2003-04-25
PCT/US2004/012783 WO2004096140A2 (en) 2003-04-25 2004-04-26 Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds

Publications (1)

Publication Number Publication Date
BRPI0409663A true BRPI0409663A (pt) 2006-04-18

Family

ID=33418310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409663 BRPI0409663A (pt) 2003-04-25 2004-04-26 método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento

Country Status (9)

Country Link
US (2) US9028863B2 (pt)
EP (1) EP1617808A4 (pt)
JP (2) JP5107573B2 (pt)
KR (1) KR20060015534A (pt)
CN (1) CN1812766A (pt)
AU (1) AU2004233873B2 (pt)
BR (1) BRPI0409663A (pt)
CA (1) CA2523413A1 (pt)
WO (1) WO2004096140A2 (pt)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6369938B1 (en) 1996-05-28 2002-04-09 Fujitsu Limited Multi-wavelength light amplifier
US6603596B2 (en) 1998-03-19 2003-08-05 Fujitsu Limited Gain and signal level adjustments of cascaded optical amplifiers
US7968529B2 (en) 2003-01-20 2011-06-28 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Use of sphingolipids for reducing high plasma cholesterol and high triacylglycerol levels
NL1022443C2 (nl) 2003-01-20 2004-07-22 Tno Sphingolipiden voor verbetering van de samenstelling van de darmflora.
CA2523413A1 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
EP1696898B1 (en) * 2003-12-02 2015-11-18 The Ohio State University Research Foundation Zn 2+ -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
WO2005118702A2 (en) * 2004-06-01 2005-12-15 The Penn State Research Foundation Unagglomerated core/shell nanocomposite particles
US7316816B2 (en) * 2004-06-10 2008-01-08 Agency For Science Technology And Research Temperature and pH sensitive copolymers
EP1618876A1 (en) * 2004-07-19 2006-01-25 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Use of sphingolipids for prevention and treatment of atherosclerosis
DE102004039875A1 (de) * 2004-08-17 2006-03-09 Universität Dortmund Nanotransportsystem mit dendritischer Architektur
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
WO2006054589A1 (ja) * 2004-11-18 2006-05-26 Terumo Kabushiki Kaisha 医薬組成物、製剤および組み合わせ製剤
EP1830829B1 (en) 2004-11-30 2012-01-04 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Sphingolipids in treatment and prevention of hepatic steatosis
US20080095834A1 (en) * 2005-03-02 2008-04-24 Volkmar Weissig Mitochondriotropic Phospholipid Vesicles
US7344583B2 (en) * 2005-03-31 2008-03-18 3M Innovative Properties Company Methods of making metal particles within cored dendrimers
US7413607B2 (en) * 2005-03-31 2008-08-19 3M Innovative Properties Company Templated semiconductor particles and methods of making
US20090311767A1 (en) * 2005-04-21 2009-12-17 Chiles Thomas C Method for molecular delivery into cells using naonotube spearing
US20060257493A1 (en) * 2005-04-28 2006-11-16 Amiji Mansoor M Nanoparticulate delivery systems for treating multi-drug resistance
JP4791082B2 (ja) * 2005-05-30 2011-10-12 株式会社クラレ リポソームおよびそれを含む皮膚外用剤
JP4931369B2 (ja) * 2005-05-31 2012-05-16 ポーラ化成工業株式会社 リポソームおよびそれを含む処置用の組成物
GR1005807B (el) * 2005-07-13 2008-02-06 Αρισταρχος Παπαγιανναρος Ρυθμιστικο λιποσωμιακο συστημα ελεγχομενης αποδεσμευσης: νεα φαρμακοτεχνικη μορφη για εγκλωβισμο αντικαρκινικων φαρμακων με βαση την τεχνολογια των λιποσωματων και των δενδριμερων
WO2007044748A2 (en) * 2005-10-11 2007-04-19 University Of Pittsburgh Sphingomyelin liposomes for the treatment of hyperactive bladder disorders
US7754483B2 (en) * 2005-11-09 2010-07-13 The Penn State Research Foundation Systems and methods for selection and maintenance of homogeneous and pluripotent human embryonic stem cells
KR100745744B1 (ko) * 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
CA2633380A1 (en) * 2005-12-16 2007-07-05 University Of Kansas Nanoclusters for delivery of therapeutics
US9603941B2 (en) * 2006-01-24 2017-03-28 Minghui Chai Method of preparing dendritic drugs
ES2776100T3 (es) 2006-03-31 2020-07-29 Massachusetts Inst Technology Sistema para el suministro dirigido de agentes terapéuticos
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
EP2081979A4 (en) * 2006-08-17 2012-07-18 Univ Utah Res Found DENDRIMERE AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2008036700A2 (en) * 2006-09-19 2008-03-27 3M Innovative Properties Company Templated metal oxide particles and methods of making
US20110223664A1 (en) * 2006-11-16 2011-09-15 The University Of Akron Materials and methods of introducing genetic material into living cells
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
US20080294089A1 (en) * 2007-06-06 2008-11-27 Biovaluation & Analysis, Inc. Dendritic Polymers for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
DK2214646T3 (da) * 2007-10-05 2021-10-04 Univ Wayne State Dendrimers for sustained release of compounds
AU2008314647B2 (en) 2007-10-12 2013-03-21 Massachusetts Institute Of Technology Vaccine nanotechnology
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US20110171309A1 (en) * 2008-04-10 2011-07-14 Board Of Regents, The University Of Texas System Compositions and Methods for Composite Nanoparticle Hydrogels
CN102076784A (zh) * 2008-05-08 2011-05-25 3M创新有限公司 表面改性的纳米粒子
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US9034374B2 (en) * 2009-06-08 2015-05-19 Ic Targets As Acoustically sensitive drug delivery particles comprising non-lamellar forming phosphatidylethanolamine
GB0910723D0 (en) * 2009-06-22 2009-08-05 Sylentis Sau Novel drugs for inhibition of gene expression
ES2351756B1 (es) * 2009-07-28 2011-10-05 Universidad Del Pais Vasco Nanopartículas lipídicas para terapia génica.
US9063138B2 (en) * 2009-10-15 2015-06-23 Robert Bosch Gmbh Device and method for indirect electronic condition control in biomolecule detection platforms
WO2011057216A1 (en) * 2009-11-06 2011-05-12 The Pennsylvania State Research Foundation Bioconjugation of calcium phosphosilicate nanoparticles for selective targeting of cells in vivo
IT1396436B1 (it) * 2009-11-16 2012-11-23 Icf Srl Composizione per la prevenzione ed il trattamento delle patologie odontostomatologiche degli animali e relativi usi.
US20110301456A1 (en) * 2010-06-07 2011-12-08 Malignext Targeting Technologies, Inc. Tissue Marking for Lesion Removal
EP2603201B1 (en) 2010-08-13 2020-03-11 Rhode Island Board of Governors for Higher Education Liposome compositions and methods of use thereof
CA2824063C (en) * 2011-01-09 2020-02-18 Anp Technologies, Inc. Hydrophobic molecule-induced branched polymer aggregates and their use
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
WO2012154942A2 (en) 2011-05-10 2012-11-15 The Penn State Research Foundation Ceramide anionic liposome compositions
EP2526971A1 (en) * 2011-05-25 2012-11-28 ArisGen SA Mucosal delivery of drugs
US9901616B2 (en) 2011-08-31 2018-02-27 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
EP2814496B1 (en) 2012-02-17 2018-04-11 University Of Georgia Research Foundation, Inc. Nanoparticles for mitochondrial trafficking of agents
US9717695B2 (en) 2012-05-18 2017-08-01 Georgia State University Research Foundation, Inc. Constructs for diagnosing and treating inflammatory bowel diseases and colon cancer
CN103113516B (zh) * 2013-02-01 2015-06-03 厦门大学 温度敏感型有机/无机杂化嵌段共聚物及制备方法与用途
EP2968143B1 (en) * 2013-03-15 2019-04-24 Memorial Sloan Kettering Cancer Center Ceramide reversal of multi-drug resistance
EP3046547A4 (en) * 2013-09-18 2017-05-24 Stc.Unm Core and surface modification of mesoporous silica nanoparticles to achieve cell specific targeting in vivo
KR101376135B1 (ko) * 2013-10-29 2014-03-19 (주) 화천 활성성분이 함유된 리포좀을 하이드로젤 입자에 물리적으로 포접하는 방법 및 이를 함유하는 화장료 조성물
EP3080219A1 (en) 2013-12-09 2016-10-19 3M Innovative Properties Company Curable silsesquioxane polymers, compositions, articles, and methods
US9851358B2 (en) 2014-01-08 2017-12-26 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for preventing or reducing metastatic dissemination
WO2015108134A1 (ja) * 2014-01-17 2015-07-23 株式会社西崎創薬研究所 Ｇｌｕｔ４エンドサイトーシス抑制剤
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
WO2015195355A1 (en) 2014-06-20 2015-12-23 3M Innovative Properties Company Adhesive compositions comprising a silsesquioxane polymer crosslinker, articles and methods
US10370564B2 (en) 2014-06-20 2019-08-06 3M Innovative Properties Company Adhesive compositions comprising a silsesquioxane polymer crosslinker, articles and methods
WO2016048736A1 (en) 2014-09-22 2016-03-31 3M Innovative Properties Company Curable polymers comprising silsesquioxane polymer core silsesquioxane polymer outer layer, and reactive groups
US9957416B2 (en) 2014-09-22 2018-05-01 3M Innovative Properties Company Curable end-capped silsesquioxane polymer comprising reactive groups
AU2016291224B2 (en) * 2015-07-09 2021-12-23 The Regents Of The University Of California Fusogenic liposome-coated porous silicon nanoparticles
US11672866B2 (en) 2016-01-08 2023-06-13 Paul N. DURFEE Osteotropic nanoparticles for prevention or treatment of bone metastases
US20190098895A1 (en) * 2016-03-09 2019-04-04 Technion Research And Development Foundation Ltd. Liposomal formulations and methods of using same in agriculture
DE102016119102A1 (de) 2016-10-07 2018-04-12 Forschungszentrum Jülich GmbH Translokation von synthetischen Polymeren durch Lipidmembrane
US11344629B2 (en) 2017-03-01 2022-05-31 Charles Jeffrey Brinker Active targeting of cells by monosized protocells
KR102723213B1 (ko) * 2017-03-29 2024-10-30 인스티튜트 오브 베이직 메디컬 사이언시즈, 차이니즈 아카데미 오브 메디컬 사이언시즈 핵산 전달제 및 그의 관련 제품의 제조에 있어서의 화합물 또는 전통 중국 의약 추출물의 적용
CN116082391A (zh) * 2017-03-29 2023-05-09 中国医学科学院基础医学研究所 化合物或中药提取物在制备核酸递送试剂中的应用及其相关产品
JP2020523430A (ja) * 2017-05-30 2020-08-06 エリューム リミテッド ナノ粒子凝集体
CN107815470B (zh) * 2017-10-11 2021-03-23 江苏大学 一种脂质体/凝胶复合型基因活化支架的制备方法
MA50532A (fr) 2017-11-03 2020-09-09 Univ Virginia Patent Foundation Compositions et méthodes pour le traitement de cancers
US11202860B2 (en) * 2018-06-06 2021-12-21 International Business Machines Corporation Controlled drug delivery in point-of-care drug delivery system based on real-time monitoring with integrated sensor
WO2020068798A1 (en) 2018-09-24 2020-04-02 Guo Jimin Living mammalian cells modified with functional modular nanoparticles
AU2019388869A1 (en) * 2018-11-26 2021-06-10 Arytha Biosciences Llc Nanoparticles containing cellular membrane and uses thereof
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
WO2020176716A1 (en) 2019-02-28 2020-09-03 Brinker C Jeffrey Modular metal–organic polyhedra superassembly compositions
WO2021101340A1 (ko) * 2019-11-22 2021-05-27 차의과학대학교 산학협력단 리포좀 조성물을 포함하는 항암 치료 보조용 조성물 및 이를 이용한 약물 전달 방법
WO2022169329A1 (ko) * 2021-02-08 2022-08-11 (주)아이엠지티 초음파 감응성 리포좀을 유효성분으로 포함하는 혈액-뇌 장벽 투과용 조성물
WO2025221772A1 (en) * 2024-04-16 2025-10-23 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Continuous production of fertilizer-loaded liposomes

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880635B1 (en) * 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4898735A (en) 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
US4812314A (en) 1986-02-24 1989-03-14 Yissum Research & Dev. Co. Of The Hebrew Univ. Of Jerusalem And Hadassah Medical Organization Lipid replacement therapy
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US5043166A (en) 1987-01-09 1991-08-27 Hadasit Medical Research, Inc. Liposome/anthraquinone drug composition and method
NO870299L (no) 1987-01-23 1988-07-25 Yissum Research And Dev Comp O Liposom/antrakinon-legemiddelpreparat og fremgangsmaate for dets fremstilling.
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US5543390A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US5593508A (en) 1991-02-11 1997-01-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Moist, absorbent material for cleaning articles and surfaces
US5244574A (en) 1991-02-11 1993-09-14 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for treating oil spills on water
US5401413A (en) 1991-02-11 1995-03-28 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for enhancing the biodegradation of biodegradable organic wastes
DE9301068U1 (de) 1993-01-27 1994-05-26 Goldwell Ag, 64297 Darmstadt Kosmetisches Mittel
US6180134B1 (en) 1993-03-23 2001-01-30 Sequus Pharmaceuticals, Inc. Enhanced ciruclation effector composition and method
US6326353B1 (en) 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
DE69418334T2 (de) 1993-08-06 2000-01-27 Opperbas Holding B.V., Amsterdam Verfahren zur hohen beladung von vesikeln mit biopolymeren substanzen
ES2113119T3 (es) 1993-08-06 1998-04-16 Opperbas Holding Bv Un metodo para la preparacion de vesiculas cargadas con estructuras biologicas, biopolimeros y/o oligomeros.
PT742789E (pt) * 1994-02-02 2000-12-29 Liposome Co Inc Lipossomas e compostos farmaceuticamente activos e metodos para a sua utilizacao
US5622715A (en) 1994-06-10 1997-04-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of improving renal function
US6235308B1 (en) 1994-06-10 2001-05-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating hypertension
AU2663895A (en) 1994-06-10 1996-01-05 Kurtz, Seymour Methods of treating hypertension and of improving impaired renal function
US6066331A (en) 1994-07-08 2000-05-23 Barenholz; Yechezkel Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers
US6156337A (en) 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) * 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US5948756A (en) 1995-08-31 1999-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipoprotein compositions
WO1997007785A1 (en) 1995-08-31 1997-03-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Therapeutic lipidic vesicles: methods of use and compositions
US5741514A (en) 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
JPH09110722A (ja) * 1995-10-20 1997-04-28 Toray Ind Inc 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法
US5817856A (en) 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
EP0910576B1 (en) * 1996-04-11 2004-08-11 University Of British Columbia Fusogenic liposomes
US5919480A (en) 1996-06-24 1999-07-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal influenza vaccine composition and method
AU3649697A (en) * 1996-06-27 1998-01-14 G.D. Searle & Co. Particles comprising amphiphilic copolymers, having a cross-linked shell domain and an interior core domain, useful for pharmaceutical and other applications
AUPO104496A0 (en) 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
US6832735B2 (en) * 2002-01-03 2004-12-21 Nanoproducts Corporation Post-processed nanoscale powders and method for such post-processing
US5965542A (en) * 1997-03-18 1999-10-12 Inex Pharmaceuticals Corp. Use of temperature to control the size of cationic liposome/plasmid DNA complexes
AU733310C (en) * 1997-05-14 2001-11-29 University Of British Columbia, The High efficiency encapsulation of charged therapeutic agents in lipid vesicles
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
US5810873A (en) * 1997-07-15 1998-09-22 Advanced Cardiovascular Systems, Inc. Stent crimping tool and method of use
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
EP0998306A1 (en) * 1997-07-24 2000-05-10 Inex Pharmaceuticals Corp. Liposomal compositions for the delivery of nucleic acid catalysts
US6734171B1 (en) * 1997-10-10 2004-05-11 Inex Pharmaceuticals Corp. Methods for encapsulating nucleic acids in lipid bilayers
WO1999027940A1 (en) 1997-12-01 1999-06-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulations for topical treatment of skin infections
US6787132B1 (en) 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
DE69841142D1 (de) 1997-12-04 2009-10-22 Hadasit Med Res Service Kombinierte chemo-immunotherapie mit liposomalen arzneistoffen und cytokinen
CA2318085C (en) * 1998-01-29 2012-05-01 Millenium Biologix Inc. A synthetic stabilized calcium phosphate biomaterial
DK1053018T3 (da) 1998-02-03 2005-08-15 Yissum Res Dev Co Administration af immunogene molekyler via HBsAg-partikler
US7029680B1 (en) 1998-02-03 2006-04-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Delivery of immunogenic molecules vis HBsAg particles
WO1999049849A1 (en) 1998-03-31 1999-10-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal bupivacaine compositions and methods of preparation
ATE355827T1 (de) 1998-08-12 2007-03-15 Yissum Res Dev Co Mittels ammoniumsulfatgradient hergestellte liposomale therapeutische zusammensetzungen
GR1003359B (el) 1998-12-24 2000-04-10 �.�. ����������� �.�.�.�. Λιποσωμιακο νιφλουμικο οξυ - νεο διαδερμικο αντιφλεγμονωδες φαρμακο [κεφαλη ψαροτουφεκου
ES2225094T3 (es) * 1999-02-08 2005-03-16 Alza Corporation Procedimiento para controlar el tamaño de liposomas.
JP2003502035A (ja) 1999-06-15 2003-01-21 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 水性媒体中でのリン脂質の酵素的製造
US6924130B1 (en) 1999-06-15 2005-08-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Enzymatic transesterification or hydrolysis of phospholipids in aqueous media
WO2001041738A2 (en) * 1999-12-10 2001-06-14 Celator Technologies Inc. Lipid carrier compositions with protected surface reactive functions
DE60110057T2 (de) 2000-01-28 2005-09-08 Alza Corp., Mountain View Liposomen enthaltend eine eingeschlossene verbindung in übersattigter lösung
US7056653B2 (en) 2000-02-10 2006-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Detection of binding of charged species using PH- or potential-sensitive probes
US6548264B1 (en) * 2000-05-17 2003-04-15 University Of Florida Coated nanoparticles
EP1361863A2 (en) 2001-02-13 2003-11-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem Carotenoid-loaded liposomes
IL159334A0 (en) 2001-06-25 2004-06-01 Yissum Res Dev Co A method for preparation of vesicles loaded with biological material and different uses thereof
WO2003000232A2 (en) 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
ATE457992T1 (de) 2001-08-23 2010-03-15 Yissum Res Dev Co Platinkomplexe und deren verwendung in der therapie
DE10144252A1 (de) 2001-08-31 2003-03-27 Fraunhofer Ges Forschung Nanopartikel mit daran immobilisiertem biologisch aktivem TNF
JP2005505602A (ja) 2001-09-06 2005-02-24 イサム・リサーチ・デベロツプメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシテイ・オブ・エルサレム 予め規定された放出プロファイルを有するリポソーム調剤の製造方法
US20040219201A1 (en) 2001-12-06 2004-11-04 Yechezkel Barenholz Tempamine compositions and methods of use
US20050169979A1 (en) 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US7179484B2 (en) * 2002-11-06 2007-02-20 Azaya Therapeutics, Inc. Protein-stabilized liposomal formulations of pharmaceutical agents
US20040101822A1 (en) * 2002-11-26 2004-05-27 Ulrich Wiesner Fluorescent silica-based nanoparticles
EP1596829A2 (en) 2003-02-28 2005-11-23 Alza Corporation Liposome composition for reduction of liposome-induced complement activation
US20060198882A1 (en) 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
US8545830B2 (en) 2003-03-24 2013-10-01 University Of Tennessee Research Foundation Multi-functional polymeric materials and their uses
CA2523413A1 (en) * 2003-04-25 2004-11-11 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
AU2004246905B2 (en) 2003-06-18 2010-01-21 Biolab Ltd. Sphingoid polyalkylamine conjugates for vaccination
US20070212403A1 (en) 2003-11-03 2007-09-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for Selecting Cationic or Anionic Liposomes for Treatment of a Mucosa Membrane, and Kit Comprising the Same
US20050129753A1 (en) 2003-11-14 2005-06-16 Gabizon Alberto A. Method for drug loading in liposomes
WO2006027786A2 (en) 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Use of liposomal glucocorticoids for treating inflammatory states
EP1793805A1 (en) 2004-09-09 2007-06-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal formulations comprising an amphipathic weak base like tempamine for treatment of neurodegenerative conditions
CA2582242A1 (en) 2004-10-08 2006-04-20 Alza Corporation Method of insertion of a lipid-linked moiety into a pre-formed lipid assembly using microwaves
EP1817004A2 (en) 2004-11-15 2007-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
WO2007004300A1 (ja) 2005-07-06 2007-01-11 Dr.Ci:Labo Co., Ltd. 化粧品
WO2007049279A2 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof
WO2007049278A2 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposomes and uses thereof
EP1962796A2 (en) 2005-12-08 2008-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods for affecting liposome composition by ultrasound irradiation
EP2079442B1 (en) 2006-09-28 2016-07-27 Hadasit Medical Research Services & Development Limited Use of glycerophospholipids for joint lubrication
US20110092768A1 (en) 2007-10-31 2011-04-21 Given Imaging Ltd. Device, system and method for in-vivo analysis
US9078812B2 (en) 2007-12-06 2015-07-14 The Bay Zoltan Foundation For Applied Research Particulate drug carriers as desensitizing agents
EP2252266A1 (en) 2008-02-11 2010-11-24 Yissum Research Development Company of the Hebrew University of Jerusalem Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents
WO2010004568A1 (en) 2008-07-10 2010-01-14 Given Imaging Ltd. Device, method and kit for in vivo detection of a biomarker
EP2344133B1 (en) 2008-10-07 2019-06-26 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. A composition of matter comprising liposomes embedded in a polymeric matrix and methods of using same
US20130052259A1 (en) 2010-02-01 2013-02-28 Yechezkel Barenholz Liposomes comprising amphipathic drugs and method for their preparation

Also Published As

Publication number Publication date
US9326953B2 (en) 2016-05-03
JP2011063615A (ja) 2011-03-31
KR20060015534A (ko) 2006-02-17
EP1617808A2 (en) 2006-01-25
EP1617808A4 (en) 2011-11-02
CA2523413A1 (en) 2004-11-11
CN1812766A (zh) 2006-08-02
JP2006524707A (ja) 2006-11-02
AU2004233873A1 (en) 2004-11-11
WO2004096140A2 (en) 2004-11-11
US20130295159A1 (en) 2013-11-07
US20050025820A1 (en) 2005-02-03
JP5888849B2 (ja) 2016-03-22
JP5107573B2 (ja) 2012-12-26
AU2004233873B2 (en) 2010-11-18
US9028863B2 (en) 2015-05-12
WO2004096140A3 (en) 2005-03-31

Similar Documents

Publication Publication Date Title
BRPI0409663A (pt) método e sistema para o envio sistêmico de compostos bioativos derivados de lipìdeo de detenção de crescimento
Li et al. Tailoring materials for modulation of macrophage fate
Ghaffari et al. Surface functionalized dendrimers as controlled-release delivery nanosystems for tumor targeting
Li et al. Self-assembling nanocarriers from engineered proteins: Design, functionalization, and application for drug delivery
Hu et al. Development of DNA tetrahedron-based drug delivery system
Whittlesey et al. Delivery systems for small molecule drugs, proteins, and DNA: the neuroscience/biomaterial interface
Faya et al. Conjugates and nano-delivery of antimicrobial peptides for enhancing therapeutic activity
Foox et al. Drug delivery from gelatin-based systems
US20190023743A1 (en) Methods and compositions for modulating drug-polymer architecture, pharmacokinetics and biodistribution
CN106793970B (zh) 用于诊断及治疗的纳米载剂及其加工
KR102264820B1 (ko) 지질과 리포좀의 안정된 제제
US20150044279A1 (en) Methods and compositions for enhancing immune response
Hu et al. Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles
Chen et al. Study of magnetic silk fibroin nanoparticles for massage-like transdermal drug delivery
BR0307724A (pt) sistemas para distribuição de imunógenos sintéticos estabilizados
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
Chan et al. Review on Medusa®: a polymer-based sustained release technology for protein and peptide drugs
AU2022378702B2 (en) Magnetostrictive piezoelectric nanoassembly as cancer chemotherapeutic
Gagliardi Novel biodegradable nanocarriers for enhanced drug delivery
Stanislawska et al. Recent advances in degradable hybrids of biomolecules and NGs for targeted delivery
Abbas et al. RETRACTED: a DNA-based nanocarrier for efficient cancer therapy
Hallaj-Nezhadi et al. Preparation and characterization of gelatin nanoparticles containing pDNA encoding IL-12 and their expression in CT-26 carcinoma cells
CA2521662A1 (en) Methods and compositions for enhancing immune response
Guo et al. Stimuli-responsive antimicrobial polymer systems: From structural design to biomedical applications
Sun et al. Evolving tumor characteristics and smart nanodrugs for tumor immunotherapy

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.